Sagimet Q2 2026: $257.6M Cash and Phase 3 Acne Trial Set for 2H 2026
SGMT has more than doubled off its 52-week low of $4.5.
Summary
Sagimet Biosciences posted a Q2 2026 net loss of $14.0 million and held $257.6 million in cash, funding operations through 2028. Its lead acne candidate, denifanstat, is on schedule for a U.S. Phase 3 trial start in the second half of 2026, and an updated investor presentation highlights a sharpened focus on dermatology.
Key Events · Earnings and Guidance · SGMT
-
Q2 2026 Financial Results
For the second quarter, the company reported a net loss of $14.0 million, with R&D expense of $11.5 million and G&A expense of $4.3 million. As of June 30, 2026, cash, cash equivalents, and marketable securities stood at $257.6 million.
-
Cash Runway Through 2028
The $257.6 million cash position—which includes $175 million from an April 2026 equity raise—is expected to fund operations through 2028 and carry the company through the denifanstat Phase 3 data readout.
-
Denifanstat Phase 3 on Track
Pending FDA agreement, the registrational Phase 3 trial of denifanstat in moderate to severe acne for the U.S. is expected to initiate in the second half of 2026.
-
TVB-3567 Advancing
The first-in-human Phase 1 trial of the follow-on FASN inhibitor TVB-3567 is ongoing, and subject to regulatory feedback, a Phase 2 trial in acne is expected to begin before the end of 2026.
Analysis · SGMT · Life Sciences
A net loss of $14.0 million in Q2 2026 reflects Sagimet's investment in its dermatology pipeline, with R&D spending at $11.5 million. The company's $257.6 million cash balance extends its runway through 2028, comfortably covering the anticipated readout of the denifanstat Phase 3 trial in moderate to severe acne. An updated investor presentation underscores the strategic pivot to dermatology: the U.S. Phase 3 trial for denifanstat remains on track to begin in the second half of 2026, while the follow-on FASN inhibitor TVB-3567 is advancing toward a Phase 2 start before year-end. Bolstered by a $175 million equity raise in April 2026, the strong cash position removes near-term financing risk and enables execution on these key clinical milestones.
At the time of this filing, SGMT was trading at $9.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $585.5M. The 52-week trading range was $4.50 to $10.06. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.